Neulasta (PEGfilgrastim) Patent Expiration, LOE Window & CMS Spending

Neulasta (PEGfilgrastim) by Amgen: Biologic BLA (Purple Book Regime), 0 AB generics, $79.2M 2024 CMS Part D & Medicaid spend, and $6,097 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayB125031 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$79.2M
2024 Medicare Part D Spend$53.1M
2024 Medicaid Spend$26.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,097 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.